Mosby's 2014 Nursing Drug Reference (51 page)

BOOK: Mosby's 2014 Nursing Drug Reference
6.79Mb size Format: txt, pdf, ePub

Available forms:
Inj 0.05, 0.1, 0.4, 0.5, 0.8, 1 mg/ml; tabs 0.4 mg; AtroPen 0.5, 1, 2 mg inj prefilled autoinjectors

Administer:
PO route

• 
Increased bulk, water in diet if constipation occurs

• 
Without regard to meals

IM route

• 
Atropine flush may occur in children and is not harmful

AtroPen

• 
Use no more than 3 AtroPen inj unless under the supervision of trained medical provider

• 
Use as soon as symptoms appear (tearing, wheezing, muscle fasciculations, excessive oral secretions)

IV route

• 
Undiluted or diluted with 10 ml sterile water; give at 0.6 mg/min through Y-tube or 3-way stopcock; do not add to IV sol; may cause paradoxical bradycardia for 2 min

Y-site compatibilities:
Amrinone, etomidate, famotidine, heparin, hydrocortisone, meropenem, nafcillin, potassium chloride, sufentanil, vit B/C

SIDE EFFECTS

CNS:
Headache, dizziness, involuntary movement, confusion, psychosis, anxiety,
coma,
flushing, drowsiness, insomnia, weakness; delirium (geriatric patients)

CV:
Hypo/hypertension, paradoxical bradycardia, angina, PVCs,
tachycardia,
ectopic ventricular beats,
bradycardia

EENT:
Blurred vision, photophobia, glaucoma, eye pain, pupil dilation, nasal congestion

GI:
Dry mouth, nausea, vomiting, abdominal pain, anorexia, constipation,
paralytic ileus,
abdominal distention, altered taste

GU:
Retention, hesitancy, impotence, dysuria

INTEG:
Rash, urticaria, contact dermatitis, dry skin, flushing

MISC:
Suppression of lactation, decreased sweating,
anaphylaxis

PHARMACOKINETICS

Half-life 2-3 hr, terminal 12.5 hr, excreted by kidneys unchanged (70%-90% in 24 hr), metabolized in liver, 40%-50% crosses placenta, excreted in breast milk

PO:
Onset 1/2-2 hr, peak 1/2-1 hr, duration 4-6 hr, well absorbed

IM/SUBCUT:
Onset 15-50 min, peak 30 min, duration 4-6 hr, well absorbed

IV:
Peak 2-4 min, duration 4-6 hr

INTERACTIONS

Increase:
Mucosal lesions—potassium chloride tab

Increase:
anticholinergic effects—tricyclics, amantadine, antiparkinson agents

Decrease:
absorption—ketoconazole, levodopa

Decrease:
effect of atropine—antacids

NURSING CONSIDERATIONS
Assess:

• 
I&O ratio; check for urinary retention, daily output

• 
ECG
for ectopic ventricular beats, PVC, tachycardia in cardiac patients

• 
For bowel sounds, constipation

• 
Respiratory status: rate, rhythm, cyanosis, wheezing, dyspnea, engorged neck veins

• 
Increased intraocular pressure:
eye pain, nausea, vomiting, blurred vision, increased tearing

• 
Cardiac rate: rhythm, character, B/P continuously

• 
Allergic reaction: rash, urticaria

Evaluate:

• 
Therapeutic response: decreased dysrhythmias, increased heart rate, secretions; GI, GU spasms; bronchodilation

Teach patient/family:

• 
To report blurred vision, chest pain, allergic reactions, constipation, urinary retention, to use sunglasses to protect the eyes

• 
Not to perform strenuous activity in high temperatures; heat stroke may result

• 
To take as prescribed; not to skip or double doses

• 
Not to operate machinery if drowsiness occurs

• 
Not to take OTC products without approval of prescriber

• 
Not to freeze or expose to light (AtroPen)

TREATMENT OF OVERDOSE:

O
2
, artificial ventilation, ECG; administer DOPamine for circulatory depression; administer diazepam or thiopental for seizures; assess need for antidysrhythmics

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

atropine ophthalmic

See
Appendix B

 

RARELY USED
auranofin (Rx)

(au-rane′oh-fin)

Ridaura

Func. class.:
Antiinflammatory, gold compound

Do not confuse:
Ridaura
/Cardura

USES:

RA; not for 1st-line therapy

Unlabeled uses:
SLE, psoriatic arthritis, pemphigus

CONTRAINDICATIONS:

Breastfeeding, children <6 yr, hypersensitivity to gold, necrotizing enterocolitis, pulmonary fibrosis, exfoliative dermatitis, recent radiation therapy, renal/hepatic disease, marked hypertension, uncontrolled CHF

 

Black Box Warning:

Bone marrow suppression, blood dyscrasias, hematuria, anemia, diarrhea

DOSAGE AND ROUTES
Calculator

• Adult: PO
6 mg/day or 3 mg bid; may increase to 9 mg/day after 3 mo

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

avanafil

(a-van′a-fil)

Stendra

Func. class.:
Impotence agent

Chem. class.:
Phosphodiesterase type 5 inhibitor

ACTION:

Inhibits phosphodiesterase type 5 (PDE5); enhances erectile function by increasing the amount of cGMP causing smooth muscle relaxation and increasing blood flow to the corpus cavernosum

USES:

Treatment of erectile dysfunction

CONTRAINDICATIONS:

Hypersensitivity, severe renal/hepatic disease, current nitrates/nitrites, patients <18 yr

Precautions:
Pregnancy (C) although not indicated for women, anatomic penile deformities, sickle cell anemia, leukemia, multiple myeloma, renal/hepatic/CV disease, bleeding disorders, active peptic ulcer, prolonged erection, aortic stenosis, HIV, stroke, geriatric patients, tinnitus, MI, visual disturbances, retinitis pigmentosa

DOSAGE AND ROUTES
Calculator
Erectile dysfunction

• Adult: PO
100 mg 30 min before sexual activity, dose may be reduced to 50 mg or increased to 200 mg; usual max dose frequency is 1 time/day

Potent CYP3A4 inhibitors/nitrates


 
Do not use

Moderate CYP3A4 inhibitors/alpha-blockers

• Adult: PO
Max 50 mg/day

Hepatic dosage/severe renal disease

• Adult: Child–Pugh C: PO
not recommended

Available forms:
Tabs 50, 100, 200 mg

Administer
PO route

• 
May be taken 30 min before sexual activity on an as-needed basis, but no more than once per day

• 
May be used without regard to meals

• 
Products should not be used with nitrates/nitrates or strong CYP3A4 inhibitors

SIDE EFFECTS

CNS:
Headache, flushing

EENT:
Nasal congestion, nasopharyngitis

MISC:
Back pain

PHARMACOKINETICS

99% protein binding, metabolized by CYP3A4, excreted as metabolites; urine 62%; 21% feces, half-life 5 hr, peak 45 min

INTERACTIONS

Do not use with nitrates/nitrites because of unsafe drop in B/P, which could result in MI, stroke

Do not use with strong CYP3A4 inhibitors (ketoconazole, ritonavir, atazanavir, clarithromycin, indivinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin)

Increase:
Avanafil level—moderate CYP3A4 inhibitors (erythromycin, amprenavir, aprepitant, diltiazem, fluconazole, fosamprenavir, verapamil)

Decrease:
B/P—alcohol, alpha-blockers, amLODIPine

Increase:
Avanafil effect—grapefruit juice

NURSING CONSIDERATIONS
Assess:

Erectile dysfunction:
Assess for underlying cause before treatment; use of organic nitrates that should not be used with this product; any loss of vision/hearing while taking this product, hypersensitivity reactions

Evaluate:

Therapeutic response:
Ability to engage in sexual intercourse

Teach patient/family:

• 
Sexual dysfunction: May be taken 30 min before sexual activity on an as-needed basis, but no more than once per day

• 
May be used without regard to meals

 
That products should not be used with nitrates/nitrates, or strong CYP3A4 inhibitors

• 
That product does not protect against sexually transmitted disease including HIV

• 
That product has no effect in the absence of sexual stimulation, to seek help if erection lasts >4 hr

• 
To tell prescriber about all medication, vitamins, herbs being taken, especially ritonavir, indinavir, ketoconazole, itraconazole, erythromycin, nitrates, α-blockers

• 
Not to drink large amounts of alcohol

 
To notify prescriber immediately and to stop taking product if vision or hearing loss occurs, if erection lasts >4 hr, or if chest pain occurs

Other books

Compendium by Alia Luria
Everybody Scream! by Jeffrey Thomas
Body Surfing by Anita Shreve
Lost Cause by John Wilson